Goldline Plus capsules 10 mg + 158.5 mg 30 pcs. in Moscow

Compound

The drug contains 10 or 15 mg of sibutramine as an active substance, as well as microcrystalline cellulose (Cellulose microcrystalline), lactose (Lactose), colloidal silicon dioxide (Silicium dioxide colloidal), magnesium stearate (Magnesii stearas).
The composition of the Goldline 10 mg capsule body includes: gelatin (Gelatine), titanium dioxide (Titanium dioxide), sodium lauryl sulfate (Sodium lauryl sulfate), dyes (sunset yellow and quinoline yellow).

To make the body of Goldline 15 mg capsules, the following are used: gelatin (Gelatine), titanium dioxide (Titanium dioxide), sodium lauryl sulfate (Sodium lauryl sulfate).

Composition of the capsule cap: gelatin (Gelatine), titanium dioxide (Titanium dioxide), sodium lauryl sulfate (Sodium lauryl sulfate), dyes (diamond blue and acid fuchsin D&C33).

Pharmacodynamics and pharmacokinetics

Goldline is a centrally acting agent for the treatment of obesity.

Its active substance sibutramine is a prodrug that exhibits its pharmacological properties in vivo due to primary and secondary amines - products of drug metabolism, which are characterized by the ability to inhibit the reuptake of monoamines (mainly serotonin and norepinephrine ).

The use of the medicine allows you to increase the feeling of satiety, reduce the need for food, and also increase thermal production. These effects are achieved by increasing the content of neurotransmitters in synapses and, consequently, increasing the activity of central serotonin (type 5-HT) and adrenergic receptors.

Sibutramine also has the ability to act on brown adipose tissue through indirect activation of β3-adrenergic receptors.

Weight loss, in turn, is accompanied by an increase in serum concentrations of high-density lipoproteins and a decrease in the concentrations of low-density lipoproteins, total cholesterol, uric acid and triglycerides.

Neither sibutramine nor its metabolic products:

• do not inhibit the enzyme monoamine oxidase (MAO);
• do not affect the release of monoamines ;
• do not have an affinity for a sufficiently large number of neurotransmitter receptors (including serotonin types 5HT1-, 5HT1A-, 5HT1B-, 5HT2A-, 5HT2C-; adrenergic beta 1, 2 and 3, as well as alpha 1 and 2; dopamine D1 and D2; benzodiazepine, muscarinic, NMDAR, histamine H1-).

After taking p/os, sibutramine is absorbed from the digestive tract by at least 77%. During the first passage through the liver, the substance is metabolized under the influence of the P4503A4 isoenzyme to mono- and didesmethylsibutramine , which are its active metabolites.

The substance is quickly distributed throughout the tissues. The protein binding rate for sibutramine is 97%, for its metabolites - 94%.

T1/2 of sibutramine - 1.1 hours, metabolites - 14 and 16 hours (for mono- and didesmethylsibutramine, respectively). After hydroxylation and conjugation, active metabolites are biotransformed into inactive ones, which are eliminated mainly by the kidneys.

Contraindications

The drug has a number of contraindications, including:

• hypersensitivity to its components;
• the patient has organic causes of obesity;
• mental illness;
• congenital heart defects;
• bulimia nervosa or anorexia nervosa ;
• Tourette's disease;
• decompensated heart failure;
• arrhythmia and tachycardia ;
• obliterating atherosclerosis of the arteries of the lower extremities;
• cardiac ischemia;
• cerebrovascular diseases (including, but not limited to, transient cerebral circulatory disorders and strokes );
• arterial hypertension (when blood pressure is more than 145/90 mm Hg);
• severe or liver dysfunction
• pheochromocytoma;
• hyperthyroidism;
• prostate adenoma , which is accompanied by the appearance of residual urine;
• angle-closure glaucoma;
• taken in combination with MAO inhibitors or other drugs that affect the central nervous system (and also if less than 14 days have passed since their discontinuation);
• simultaneous use of other anorexigenic drugs;
• established alcohol, drug or drug addiction;
• age over 65 years and under 18 years.

It is recommended to prescribe Goldline with caution to patients with mild to moderately severe disorders of liver and/or kidney function, neurological disorders (including mental retardation and increased seizure activity, including a history), motor or verbal tics (including a history), insufficiency chronic blood circulation, coronary artery diseases (including a history), cholelithiasis , arrhythmia ; controlled arterial hypertension , as well as if hypertension is noted in the anamnesis.

Goldline Plus capsules 10mg+158.5mg No. 60

Compound

Sibutramine hydrochloride monohydrate + microcrystalline cellulose

Indications for use

indicated for weight loss in the following conditions:

— nutritional obesity with a body mass index (BMI) of 30 kg/m2 or more;

- nutritional obesity with a body mass index of 27 km/m2 or more in combination with type 2 diabetes mellitus and dyslipidemia.

Contraindications

- established hypersensitivity to sibutramine or other components of the drug;

- presence of organic causes of obesity (for example, hypothyroidism);

- serious eating disorders - anorexia nervosa or bulimia nervosa;

- mental illness;

— Gilles de la Tourette syndrome (generalized tics);

- simultaneous use of MAO inhibitors (for example, phentermine, fenfluramine, dexfenfluramine, ethylamphetamine, ephedrine) or use within 2 weeks before taking Goldline PLUS and 2 weeks after the end of its use of other drugs acting on the central nervous system, inhibiting the return serotonin uptake (eg, antidepressants, antipsychotics); sleeping pills containing tryptophan, as well as other centrally acting drugs for weight loss or for the treatment of mental disorders;

- cardiovascular diseases (history or current): coronary heart disease (myocardial infarction (MI), angina pectoris); chronic heart failure in the stage of decompensation, occlusive diseases of peripheral arteries, tachycardia, arrhythmia, cerebrovascular diseases (stroke, transient cerebrovascular accidents);

- uncontrolled arterial hypertension (blood pressure (BP) above 145/90 mmHg);

- angle-closure glaucoma;

- thyrotoxicosis;

- severe dysfunction of the liver and/or kidneys;

- benign prostatic hyperplasia;

- pheochromocytoma;

— established pharmacological, drug or alcohol dependence;

- pregnancy and breastfeeding;

- age under 18 and over 65 years.

The drug should be prescribed with caution in the following conditions: a history of arrhythmias, chronic circulatory failure, coronary artery diseases (including a history), except for coronary heart disease (MI, angina); glaucoma, except for angle-closure glaucoma, cholelithiasis, arterial hypertension (controlled and with a history), neurological disorders, including mental retardation and seizures (including a history), epilepsy, impaired liver and/or kidney function of mild to moderate severity , a history of motor and verbal tics, a tendency to bleeding, bleeding disorders, taking drugs that affect hemostasis or platelet function.

Directions for use and doses

Goldline PLUS is taken orally once a day. The dose is set individually, depending on tolerability and clinical effectiveness. The recommended starting dose of sibutramine is 10 mg/day. Capsules should be taken in the morning, without chewing and with a sufficient amount of liquid (a glass of water). The drug can be taken on an empty stomach or combined with meals. If within 4 weeks from the start of treatment a reduction in body weight of less than 2 kg is not achieved, then the dose of sibutramine is increased to 15 mg/day. Treatment with Goldline PLUS should not continue for more than 3 months in patients who do not respond well to therapy, i.e. who fail to achieve a 5% reduction in body weight from the initial value within 3 months of treatment. Treatment should not be continued if, with further therapy, after achieving a reduction in body weight, the patient again gains 3 kg or more in body weight. The duration of treatment should not exceed 1 year, since there are no data on efficacy and safety for longer periods of taking sibutramine. Treatment with Goldline PLUS should be carried out in combination with diet and exercise under the supervision of a physician with practical experience in the treatment of obesity.

special instructions

Goldline PLUS should be used only in cases where all non-drug measures for weight loss are ineffective - if the weight loss over 3 months is less than 5 kg. Treatment with Goldline PLUS should be carried out as part of complex weight loss therapy under the supervision of a physician with practical experience in the treatment of obesity. Complex therapy includes both changing diet and lifestyle, as well as increasing physical activity. An important component of therapy is to create the prerequisites for persistent changes in eating behavior and lifestyle, which are necessary to maintain the achieved weight loss even after drug therapy is discontinued. As part of Goldline PLUS therapy, patients need to change their lifestyle and habits in such a way as to ensure that the achieved weight loss is maintained after completion of treatment. Patients should be clear that failure to comply with these requirements will lead to repeated weight gain and repeated visits to their doctor. Patients taking Goldline PLUS should have their blood pressure and heart rate measured regularly. During the first 3 months of treatment, these parameters should be monitored every 2 weeks and then monthly. If during two consecutive visits an increase in resting heart rate is detected? 10 beats per minute or systolic/diastolic pressure? 10 mmHg Art., it is necessary to stop treatment. In patients with arterial hypertension whose blood pressure is above 145/90 mm Hg during antihypertensive therapy. Art., this control should be carried out especially carefully and, if necessary, at shorter intervals. In patients whose blood pressure exceeded 145/90 mmHg twice during repeated measurements. Art., treatment with Goldline PLUS should be cancelled. In patients with sleep apnea, blood pressure must be monitored especially carefully. The simultaneous administration of drugs that increase the QT interval requires special attention. These drugs include H1-histamine blockers (astemizole, terfenadine); antiarrhythmic drugs that increase the QT interval (amiodarone, quinidine, flecainide, mexiletine, propafenone, sotalol); gastrointestinal motility stimulator cisapride; pimozide, sertindole and tricyclic antidepressants. This also applies to conditions that can lead to an increase in the QT interval, such as hypokalemia and hypomagnesemia. The interval between taking MAO inhibitors (including furazolidone, procarbazine, selegiline) and Goldline PLUS should be at least 2 weeks. Although a connection has not been established between taking sibutramine and the development of primary pulmonary hypertension, however, given the well-known risk of drugs in this group, with regular medical monitoring it is necessary to pay special attention to symptoms such as progressive dyspnea (breathing difficulty), chest pain and swelling in the legs . If you miss a dose of Goldline PLUS, you should not take a double dose of the drug at the next dose; it is recommended to continue taking the drug according to the prescribed regimen. The duration of taking Goldline PLUS should not exceed 1 year. When taking sibutramine and other serotonin reuptake inhibitors together, there is an increased risk of bleeding. In patients predisposed to bleeding or taking drugs that affect hemostasis or platelet function, sibutramine should be used with caution. Although there is no clinical evidence of addiction to sibutramine, the patient's history of drug dependence should be assessed and attention should be paid to possible signs of drug abuse.

Dosage form

capsules

Action

Goldline PLUS is a combination drug whose effect is determined by its constituent components. Sibutramine belongs to the list of potent substances, is a prodrug and exhibits its effect in vivo due to metabolites (primary and secondary amines) that inhibit the reuptake of monoamines (serotonin, norepinephrine, dopamine). An increase in the content of neurotransmitters in synapses increases the activity of central 5HT-serotonin and adrenergic receptors, which increases the feeling of satiety and reduces the need for food, as well as an increase in thermal production. By indirectly activating beta3-adrenergic receptors, sibutramine acts on brown adipose tissue. A decrease in body weight is accompanied by an increase in plasma concentrations of high-density lipoproteins (HDL) and a decrease in the amount of triglycerides, total cholesterol, low-density lipoproteins (LDL) and uric acid. Sibutramine and its metabolites do not affect the release of monoamines and do not inhibit monoamine oxidase (MAO); have low affinity for a large number of neurotransmitter receptors, including serotonin (5-HT1, 5-HT1A, 5-HT1B, 5-HT2C), adrenergic (beta1, beta2, beta3, alpha1, alpha2), dopamine (Dl, D2), muscarinic , histamine (H1), benzodiazepine and glutamate (NMDA) receptors.

Microcrystalline cellulose is an enterosorbent, has sorption properties and a nonspecific detoxification effect. Binds and removes from the body various microorganisms, their metabolic products, toxins of exogenous and endogenous nature, allergens, xenobiotics, as well as an excess of certain metabolic products and metabolites responsible for the development of endogenous toxicosis.

Use during pregnancy and breastfeeding

Since to date there is not a sufficiently large number of studies regarding the safety of the effects of sibutramine on the fetus, this drug is contraindicated during pregnancy. Women of reproductive age must use contraception while taking Goldline PLUS. It is contraindicated to take Goldline PLUS while breastfeeding.

Interaction

Inhibitors of microsomal oxidation, incl. inhibitors of the CYP3A4 isoenzyme (ketoconazole, erythromycin, cyclosporine, etc.) increase plasma concentrations of sibutramine metabolites with an increase in heart rate and a clinically insignificant increase in the QT interval. Rifampicin, macrolide antibiotics, phenytoin, carbamazepine, phenobarbital and dexamethasone can accelerate the metabolism of sibutramine. The simultaneous use of several drugs that increase the level of serotonin in the blood plasma can lead to the development of serious interactions. The so-called serotonin syndrome can develop in rare cases when sibutramine is used simultaneously with selective serotonin reuptake inhibitors (drugs for the treatment of depression), with certain drugs for the treatment of migraines (sumatriptan, dihydroergotamine), with potent analgesics (pentazocine, pethidine, fentanyl) or antitussives drugs (dextromethorphan). Sibutramine does not affect the effect of oral contraceptives. When sibutramine and alcohol were taken simultaneously, there was no increase in the negative effects of alcohol. However, alcohol is absolutely not compatible with the dietary measures recommended when taking sibutramine. When used simultaneously with sibutramine, other drugs that affect hemostasis or platelet function increase the risk of bleeding. Drug interactions with the simultaneous use of sibutramine with drugs that increase blood pressure and heart rate have not been fully studied at present. This group of drugs includes decongestants, cough, cold, and allergy medications that contain ephedrine or pseudoephedrine. Therefore, in cases of simultaneous use of these drugs with sibutramine, caution should be exercised. The combined use of sibutramine with drugs for weight loss that act on the central nervous system or drugs for the treatment of mental disorders is contraindicated.

Overdose

There are extremely limited data on sibutramine overdose. The most common adverse reactions associated with overdose: tachycardia, increased blood pressure, headache, dizziness. You should notify your doctor in case of suspected overdose. In case of overdose, you must immediately stop using the drug. There is no special treatment or specific antidotes. It is necessary to carry out general measures: ensure free breathing, monitor the state of the cardiovascular system, and, if necessary, carry out supportive symptomatic therapy. Timely use of activated carbon, as well as gastric lavage, can reduce the intake of sibutramine in the body. Patients with high blood pressure and tachycardia can be prescribed beta-blockers. The effectiveness of forced diuresis or hemodialysis has not been established.

Impact on the ability to drive vehicles and operate machinery

Taking Goldline PLUS may limit the ability to drive vehicles and operate machinery. During the period of use of Goldline PLUS, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Side effects

The most common side effects associated with the use of the drug Goldline occur in the first weeks of treatment (they are usually observed during the first month). Over time, their severity and frequency of occurrence decrease.

In general, side effects associated with taking the drug do not pose a threat to health and are reversible.

The most common adverse events (occurring in at least every 10 patients):

• insomnia;
• loss of appetite;
• feeling of dry mouth;
• constipation.

Sometimes (occur with a frequency of 1-10%) the following may appear:

• headache;
• increased anxiety;
• dizziness;
• paresthesia;
• vasodilator effect (including hyperemia of the skin);
• moderate increase in heart rate (on average 3-7 beats per minute);
• tachycardia;
• increased blood pressure (at rest, they increase by an average of 1-3 mm Hg);
• heartbeat;
• exacerbation of hemorrhoids ;
• nausea and change in taste;
• increased sweating.

At the initial stages of treatment with Goldline, a more significant change in blood pressure and pulse rate is possible (usually such phenomena are observed in the first 4-8 weeks of taking the drug).

In isolated cases, such clinically significant side effects were recorded as: skin itching, development of flu-like syndrome , dysmenorrhea , back and abdominal pain, edema, paradoxical increase in appetite, drowsiness, bleeding, convulsions, increased thirst, runny nose, depression, mood lability, irritability , nervousness, anxiety, acute interstitial nephritis , rheumatic purpura , transient increase in the activity of liver enzymes in the blood , thrombocytopenia .

One patient with schizoaffective psychosis , which most likely existed before the start of drug treatment, developed acute psychosis .

The body's response to stopping Goldline, which manifests itself in the form of headaches and increased appetite, rarely develops.

evidence that withdrawal symptoms , withdrawal symptoms , or mood disturbances may occur after stopping treatment.

Possible side effects

The instructions describe in detail all possible negative reactions. Most often they make themselves felt during the first four weeks of use. The usual way of life is disrupted. And the body needs time to get used to and adapt. If all new sensations are mild and do not interfere with a full daily routine, then you need to be patient. In a month they will disappear. In this case, there is no need to change the dosage or regimen of use. If problems remain after this period, a mandatory consultation with a doctor is required. Negative phenomena include:

• insomnia;
• excessive sweating;
• attacks of headache;
• feeling of anxiety;
• dry mouth;
• bowel dysfunction (constipation, diarrhea);
• dizziness;
• cardiopalmus;
• increased blood pressure;
• nausea.

Goldline tablets, instructions for use

How to take Goldline capsules

The starting dose of the drug is 10 mg/day. If the expected effect is not observed when using it (in situations where body weight decreases by less than 2 kg during a month of treatment), as well as if the drug is well tolerated, the dose is increased to 15 mg/day.

If there is no effect even when using a higher dosage (weight decreases by less than 2 kg per month), treatment with sibutramine is stopped.

In patients who do not adequately respond to the prescribed treatment, that is, within three months their weight decreases by less than five percent of the original, the duration of use of Goldline should not exceed 3 months.

The maximum duration of treatment is two years. This is due to the lack of reliable data on the safety and effectiveness of using sibutramine over a longer period of time.

You should not continue taking the drug if, after achieving weight loss during further treatment, the patient again gains three (or more) kilograms.

It is considered advisable to supplement therapy with physical activity and diet. Training should be carried out under the supervision of a specialist who has sufficient practical experience in treating people suffering from obesity.

Instructions for Goldline Light

Goldline Light is a drug produced by the pharmaceutical company Izvarino Pharma LLC.

The official website of the tablets states that this product is not a drug and is used by overweight people who actively use physical activity to lose weight, as a dietary supplement.

The daily dose of the drug contains 48 mg of lipoic acid and 360 mg of l-carnitine (vitamin BT).

In combination with moderate physical activity and a low-calorie diet, weight loss with the use of the product increases by 22% with regular use for six months. In this case, the concentration of α-lipoic acid should be at least 1% of the weight of the total amount of food eaten.

With moderate intensity physical activity, fat burning increases by 36-55%.

In addition, α-lipoic acid is a good antioxidant, which, due to its ability to dissolve in both non-polar and polar solvents, exhibits its properties both in cells and in the extracellular space.

cATP-dependent protein kinase which influences human eating behavior , resulting in increased energy expenditure and decreased food consumption.

The effect of using the drug is dose-dependent.

In accordance with the instructions, take 1 or 2 Goldline Light capsules approximately 15-20 minutes before the start of training and then within 60-90 minutes after it ends.

Lipoic acid is a medication prescribed for cirrhosis or fatty liver , hepatitis A , and chronic hepatitis . Lipoic acid is not available without a prescription because it often causes the following side effects:

• severe allergic reactions (this may be itching, urticaria or systemic allergic reactions);
• dyspepsia.

At the same time, in the instructions supplied with the Goldline Light dietary supplement, the manufacturer does not warn about the possibility of developing such side effects.

You should also remember that taking capsules should not be combined with taking any multivitamin complexes, drugs for the treatment of anemia and other drugs that contain calcium, potassium, iron or magnesium ions.

Overdose

To date, there is not enough data on sibutramine . An increase in the severity of adverse reactions is considered the most likely.

If a suspected overdose of Goldline occurs, you should notify your doctor.

There are no specific antidotes or special treatment. It is recommended to ensure the patient can breathe freely and keep the condition of the cardiovascular system under control. Further therapy is symptomatic.

Timely intake of activated carbon and gastric lavage procedure can reduce the absorption of the drug in the intestinal tract.

Patients who have high blood pressure may be prescribed β-blockers .

The effectiveness of hemodialysis or forced diuresis has not been established.

Interaction

The simultaneous use of sibutramine with inhibitors of microsomal oxidation (including the CYP3A4 isoenzyme) increases the plasma concentration of its metabolites, heart rate and provokes a clinically insignificant increase in the QT interval.

The metabolism of sibutramine is accelerated when used in combination with phenytoin , Dexamethasone , Carbamazepine , Rifampicin , Phenobarbital and macrolide antibiotics .

Serious interactions are possible in the case of simultaneous administration of several drugs that increase the concentration of serotonin in the blood.

In rare cases, serotonin syndrome develops when sibutramine is used in combination with:

• selective serotonin reuptake inhibitors, which are used to treat depression and anxiety disorders;
• certain antimigraine drugs (for example, dihydroergotamine or sumatriptan );
• antitussives ( dextromethorphan );
• opioid analgesics ( Fentanyl , pentazocine , pethidine ).

Sibutramine does not affect the action of oral contraceptives.

With simultaneous use of sibutramine with ephedrine , pseudoephedrine , phenylpropanolamine and combination drugs containing these substances, the risk of increased blood pressure and heart rate increases.

The substance does not enhance the negative effects of ethanol, however, drinking alcohol during treatment with Goldline reduces the effectiveness of dietary measures.

Goldline plus caps 15mg+153.5mg N30 (Izvarino)

Goldline® PLUS should be used only in cases where all non-drug measures for weight loss are ineffective - if the weight loss over 3 months is less than 5 kg. Treatment with Goldline® PLUS should be carried out as part of complex weight loss therapy under the supervision of a physician with practical experience in the treatment of obesity. Complex therapy includes both changing diet and lifestyle, as well as increasing physical activity. An important component of therapy is to create the prerequisites for persistent changes in eating behavior and lifestyle, which are necessary to maintain the achieved weight loss even after drug therapy is discontinued. As part of treatment with Goldline® PLUS, patients need to change their lifestyle and habits in such a way as to ensure that the achieved weight loss is maintained after completion of treatment. Patients should be clear that failure to comply with these requirements will lead to repeated weight gain and repeated visits to their doctor. Patients taking Goldline® PLUS should have their blood pressure and heart rate measured regularly. During the first 3 months of treatment, these parameters should be monitored every 2 weeks and then monthly. If during two consecutive visits an increase in resting heart rate >\000910 beats per minute or systolic/diastolic pressure > 10 mm Hg is detected. Art., it is necessary to stop treatment. In patients with arterial hypertension whose blood pressure is above 145/90 mm Hg during antihypertensive therapy. Art., this control should be carried out especially carefully and, if necessary, at shorter intervals. In patients whose blood pressure exceeded 145/90 mmHg twice during repeated measurements. Art., treatment with Goldline® PLUS should be discontinued (see section “Side Effects”). In patients with sleep apnea, blood pressure must be monitored especially carefully. The simultaneous administration of drugs that increase the QT interval requires special attention. These drugs include Hi-histamine blockers (astemizole, terfenadine); antiarrhythmic drugs that increase the QT interval (amiodarone, quinidine, flecainide, mexiletine, propafenone, sotalol); gastrointestinal motility stimulator cisapride; pimozide, sertindole and tricyclic antidepressants. This also applies to conditions that can lead to an increase in the QT interval, such as hypokalemia and hypomagnesemia (see also section “Interaction with other drugs”). The interval between taking MAO inhibitors (including furazolidone, procarbazine, selegiline) and Goldline® PLUS should be at least 2 weeks. Although a connection has not been established between taking sibutramine and the development of primary pulmonary hypertension, however, given the well-known risk of drugs in this group, with regular medical monitoring it is necessary to pay special attention to symptoms such as progressive dyspnea (breathing difficulty), chest pain and swelling in the legs . If you miss a dose of Goldline® PLUS, you should not take a double dose of the drug at the next dose; it is recommended to continue taking the drug according to the prescribed regimen. The duration of taking Goldline® PLUS should not exceed 1 year. When taking sibutramine and other serotonin reuptake inhibitors together, there is an increased risk of bleeding. In patients predisposed to bleeding or taking drugs that affect hemostasis or platelet function, sibutramine should be used with caution. Although there is no clinical evidence of addiction to sibutramine, the patient's history of drug dependence should be assessed and attention should be paid to possible signs of drug abuse. Effect on the ability to drive vehicles and machinery Taking Goldline® PLUS may limit the ability to drive vehicles and machinery. During the period of use of the drug Goldline® PLUS, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

special instructions

Goldline diet pills are prescribed only in cases where all other measures aimed at weight loss are ineffective. Treatment should be carried out under the supervision of a specialist who has sufficient experience in weight correction for obesity as part of complex treatment (including physical activity, review of diet, habitual lifestyle, diet).

The period of taking Goldline at a dose of 15 mg should be limited in time.

In the first 8 weeks of treatment, heart rate and blood pressure should be monitored every 2 weeks. After this time, monitoring is carried out once a month.

For patients with arterial hypertension (when the pressure is at the level of 145/90 mm Hg), blood pressure and heart rate are recommended to be monitored more often and more carefully. If the pressure rises above the specified values ​​2 times, treatment with Goldline is stopped.

The appearance of chest pain, swelling of the legs, and progressive dyspnea may indicate the development of pulmonary hypertension (such conditions require consultation with a doctor).

Women of childbearing age should use effective contraception throughout the entire course of use.

Sibutramine has the ability to reduce salivation, cause a feeling of discomfort in the oral cavity, provoke the development of caries and periodontal , thrush .

During the treatment period, you should refrain from performing work that could potentially threaten your health and life, as well as from driving a car.

Goldline® PLUS (Goldliine PLUS)

Goldline® PLUS should be used only in cases where all non-drug measures for weight loss are ineffective - if the weight loss over 3 months is less than 5 kg.

Treatment with Goldline® PLUS should be carried out as part of complex weight loss therapy under the supervision of a physician with practical experience in the treatment of obesity. Complex therapy includes both changing diet and lifestyle, as well as increasing physical activity. An important component of therapy is to create the prerequisites for persistent changes in eating behavior and lifestyle, which are necessary to maintain the achieved weight loss even after drug therapy is discontinued. As part of treatment with Goldline® PLUS, patients need to change their lifestyle and habits in such a way as to ensure that the achieved weight loss is maintained after completion of treatment. Patients should be clear that failure to comply with these requirements will lead to repeated weight gain and repeated visits to their doctor.

Patients taking Goldline® PLUS should have their blood pressure and heart rate measured regularly. During the first 3 months of treatment, these parameters should be monitored every 2 weeks and then monthly. If during two consecutive visits an increase in resting heart rate ≥ 10 beats per minute or systolic/diastolic pressure ≥ 10 mmHg is detected. Art., it is necessary to stop treatment.

In patients with arterial hypertension whose blood pressure is above 145/90 mm Hg during antihypertensive therapy. Art., this control should be carried out especially carefully and, if necessary, at shorter intervals.

In patients whose blood pressure exceeded 145/90 mm Hg twice during repeated changes. Art., treatment with Goldline® PLUS should be discontinued (see section “Side Effects”).

In patients with sleep apnea, blood pressure must be monitored especially carefully.

The simultaneous administration of drugs that increase the QT interval requires special attention. These drugs include H1-histamine blockers (astemizole, terfenadine); antiarrhythmic drugs that increase the QT interval (amiodarone, quinidine, flecainide, mexiletine, propafenone, sotalol); gastrointestinal motility stimulator cisapride; pimozide, sertindole and tricyclic antidepressants. This also applies to conditions that can lead to an increase in the QT interval, such as hypokalemia and hypomagnesemia (see also section “Interaction with other drugs”).

The interval between taking MAO inhibitors (including furazolidone, procarbazine, selegiline) and Goldline® PLUS should be at least 2 weeks.

Although a connection has not been established between taking sibutramine and the development of primary pulmonary hypertension, however, given the well-known risk of drugs in this group, with regular medical monitoring it is necessary to pay special attention to symptoms such as progressive dyspnea (breathing difficulty), chest pain and swelling in the legs .

If you miss a dose of Goldline® PLUS, you should not take a double dose of the drug at the next dose; it is recommended to continue taking the drug according to the prescribed regimen.

The duration of taking Goldline® PLUS should not exceed 1 year.

When taking sibutramine and other serotonin reuptake inhibitors together, there is an increased risk of bleeding. In patients predisposed to bleeding or taking drugs that affect hemostasis or platelet function, sibutramine should be used with caution.

Although there is no clinical evidence of addiction to sibutramine, the patient's history of drug dependence should be assessed and attention should be paid to possible signs of drug abuse.

Analogs

Level 4 ATC code matches:
Sibutramine

Meridia

Lindaxa

Analogues by mechanism of action:

• Reduxin
• Fepranon
• Goldline-Light

Structural analogues (generics):

• Lindaxa
• Meridia
• Slimia

During pregnancy

The category of action on the developing fetus in accordance with the FDA classification is C. This means that animal studies have established a negative effect of the drug on the fetus, but strictly controlled studies of the use of the drug during pregnancy in humans have not been conducted.

It has also not been established whether sibutramine or its metabolites can pass into breast milk.

This excludes the possibility of using the drug by pregnant women and during breastfeeding.

Contraindications for use

The list of reasons why you should not resort to body contouring using Goldline should be taken seriously. It includes:

Use during pregnancy and breastfeeding

During this period, every woman should be more attentive to herself and her health, limiting the use of medications. To date, for ethical reasons, no studies have been conducted to study the effect of the active substance on the fetus.

It is unknown whether it passes through the placenta and breast milk. Therefore, taking diet pills is contraindicated for women who are expecting the birth of a child or who are breastfeeding.

Use for children

The lack of research into the safety of sibutramine in children under 18 years of age prevents them from being treated for obesity with Goldline Plus.

Use for the elderly

The main contraindication in this age category is patients over 65 years of age. This is due to the fact that most obese people at this point have a number of health problems.

• anorexia or bulimia caused by nervous disorders;
• cardiovascular diseases;
• renal failure;
• pathology of the liver or gall bladder;
• glaucoma;
• disturbances in the functioning of the circulatory system.

Reviews about Goldline

Comments and reviews from those losing weight about Goldline 15 mg and 10 mg are quite contradictory. Some note the high effectiveness of the product (some women claim that by taking capsules for weight loss, they lost 7-8 kg in 3-8 weeks), while others say that taking the drug did not give them the desired result, but only provoked a lot of unpleasant symptoms ( pressure surges, headaches, dizziness, weakness, etc.).

In addition, in some reviews of Goldline diet pills, women complain that after stopping taking the capsules, their appetite noticeably increased, and the lost pounds returned almost immediately.

Doctors in reviews of Goldline tablets write that sibutramine is a potent substance that can be sold in pharmacies only with a prescription. It has quite a lot of contraindications and often provokes side effects.

Thus, they recommend taking the drug for weight loss only after consultation with a specialist and a thorough assessment of your health.

The use of the drug is advisable for obesity (that is, when the patient’s BMI is more than 30 kg/sq. m, in exceptional cases - at least 27 kg/sq. m) and only in the absence of endocrine diseases, heart and vascular diseases, mental disorders and certain individual indicators that can be identified by the attending physician.

Only the attending physician can select the optimal dosage regimen (15 or 10 mg) and determine how long the treatment will be.

Often among reviews of Goldline there are also reviews of Goldline Light. Unlike Goldline, it is not a medicine, but a dietary supplement. As noted by women and girls who have taken the drug, the effect of its use is noticeable only if a low-calorie diet is followed and a sufficient level of physical activity is provided.

Simply taking capsules will not help you lose weight.

What drugs should not be taken at the same time?

To avoid possible interactions between drugs used at the same time, it is important to be aware of the possibility of their interaction. Goldline Plus is allowed to be taken by women who take oral contraceptives . It has been proven that the active substance has no effect on them.

It is not recommended to take Goldline with medications intended to treat depression or other mental disorders. Otherwise, it may cause serotonin syndrome.

Combined pharmacy items for getting rid of colds or drugs containing ephedrine, when taken simultaneously with a weight loss product, provoke an increase in blood pressure.

Taking antibiotics of a certain group can lead to an acceleration of the metabolism of sibutramine.

In any case, before starting the Goldline course, it is important to inform the specialist about the contents of your first aid kit, which you actively use.

Goldline price, where to buy

Price of diet pills in Russian pharmacies:

• from 1400 rub. per capsule 10 mg No. 30;
• from 3100 rub. per capsule 10 mg No. 90;
• from 2000 rub. per capsule 15 mg No. 30;
• from 3700 rub. per capsule 15 mg No. 60;
• from 5300 rub. for capsules 15 mg No. 90.

The tablets are available with a prescription. If desired, they can be ordered online without a prescription. In large cities (for example, Krasnoyarsk, Moscow or Yekaterinburg), online pharmacies offer to buy Goldline with home delivery.

• Online pharmacies in RussiaRussia

ZdravCity

• Goldline Plus capsules 15mg+153.5mg 30 pcs. Izvarino Pharma LLC
  RUB 2,232 order
• Goldline Plus capsules 15mg+153.5mg 60 pcs. Izvarino Pharma LLC

  RUR 3,908 order

• Goldline Plus capsules 15mg+153.5mg 90 pcs. Izvarino Pharma LLC

  RUR 5,630 order

• Goldline Plus capsules 10mg+158.5mg 30 pcs. Izvarino Pharma LLC

  RUB 1,487 order

• Goldline Plus capsules 10 mg + 158.5 mg 90 pcs. Izvarino Pharma LLC

  RUB 3,362 order